InvestorsHub Logo
Followers 15
Posts 700
Boards Moderated 0
Alias Born 10/03/2017

Re: ORBAPU post# 405822

Wednesday, 03/15/2023 6:32:35 PM

Wednesday, March 15, 2023 6:32:35 PM

Post# of 428783
Ridker is advocating for Esperion’s BA (Bempedoic Acid - Nexletol) and was lead author of recent CLEAR harmony paper

https://pace-cme.org/bempedoic-acid/

https://www.sciencedirect.com/science/article/abs/pii/S1933287423000326

Journal of Clinical Lipidology
Available online 14 February 2023

Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial

Paul M Ridker MD, Lei Lei PhD, Kausik K. Ray MD, Christie M. Ballantyne MD, Gary Bradwin MS, Nader Rifai PhD

This study was sponsored by Esperion Therapeutics, Inc.

ClinicalTrials.gov Identifier: NCT02666664; https://clinicaltrials.gov/ct2/show/NCT02666664.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News